Pacira BioSciences Inc. (NASDAQ:PCRX) is deemed one of the most undervalued small-cap stocks by analysts. New long-term follow-up data from their Phase 1 clinical trial of PCRX-201, a gene therapy for knee osteoarthritis, shows sustained improvements up to 156 weeks post-treatment.

PCRX-201 utilizes Pacira’s HCAd gene therapy vector platform, locally injecting into the knee joint to boost IL-1Ra production. This blocks interleukin-1 pathway activation, reducing chronic inflammation, pain, and improving function in patients with knee osteoarthritis.

Pacira BioSciences Inc. (NASDAQ:PCRX) develops non-opioid pain management and regenerative health solutions in the US. While PCRX shows investment potential, certain AI stocks may offer greater upside with lower downside risks. For a free report on the best short-term AI stock, click the link provided.

Read more at Yahoo Finance: Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement